VLP Super Antigen

For specific product details please scroll to the bottom of the page!

The rapid development of R&D for antibody drugs has entered the next era. With increasingly fierce competition in the field of innovative antibody drug research and development, the discovery of differentiated antibodies or the discovery of antibodies specific to difficult targets will be a better choice to maintain competitiveness. Therefore, the importance of antigen proteins as raw materials for the early development of antibody drugs cannot be overemphasized.

VLP stands for Virus-Like Particle, which is derived from the outer capsid protein of the virus and is a tiny nanoparticle formed by the automatic assembly of one or more capsid proteins. VLP particles do not contain viral infectious genomes, so they are safe during manufacturing operations. With the development of technology based on the effect of VLP in efficiently activating the body's humoral and cellular immune responses, the role of VLP-displayed antigens in the discovery of antibodies for difficult targets is obvious and has great advantages.

VLP-displayed antigens can overcome the problems of low abundance and weak immunogenicity of many proteins, especially for multiple transmembrane proteins. KACTUS utilized our self-developed SAMS^TM (a new functional recombinant protein and antibody R&D and production platform) to develop a series of biotinylated and non-biotinylated VLP display antigen products which can flexibly meet customers needs for antibody research and development, and are suitable for SPR , BLI and ELISA program research.

Product Applications

• -Antibody discovery: immunization, screening, functional characterization
• -Affinity determination: ELISA, SPR, BLI
• -Blood sample determination: ELISA

Product Case Study

Human CD24 VLP

Fig.1 VLP-CD24. bioactivity assay by ELISA.

Fig.2 Enhanced immunogenicity of Kactus VLP-CD24.